IGF2 LOI (n=13) was associated with a higher risk for loss of MTMR7 in the tumor (OR: 13.71, *p= 0.0157) compared with the control group of CRC cases with neither IGF2 LOI nor T2DM (n=16). The gene discussed is IGF2; the disease is type 2 diabetes mellitus.